Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]